

RÃ©my A Bonnin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3500124/publications.pdf>

Version: 2024-02-01

145
papers

11,010
citations

57758

44
h-index

31849

101
g-index

147
all docs

147
docs citations

147
times ranked

8132
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of expanded-spectrum cephalosporin hydrolysis by lateral flow immunoassay. <i>Microbial Biotechnology</i> , 2022, 15, 603-612.	4.2	7
2	Characterization of VIM-1-, NDM-1- and OXA-48-producing <i>Citrobacter freundii</i> in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1199-1201.	3.0	5
3	Specificities and Commonalities of Carbapenemase-Producing <i>Escherichia coli</i> Isolated in France from 2012 to 2015. <i>MSystems</i> , 2022, 7, e0116921.	3.8	7
4	Emergence of VIM-producing <i>Enterobacter cloacae</i> complex in France between 2015 and 2018. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 944-951.	3.0	12
5	Co-occurrence of genes encoding carbapenemase, ESBL, pAmpC and non- β -Lactam resistance among <i>Klebsiella pneumoniae</i> and <i>E. coli</i> clinical isolates in Tunisia. <i>Letters in Applied Microbiology</i> , 2022, 74, 729-740.	2.2	5
6	Multiplex Lateral Flow Immunoassay for the Detection of Expanded-Spectrum Hydrolysis and CTX-M Enzymes. <i>Diagnostics</i> , 2022, 12, 190.	2.6	3
7	To Be or Not to Be an OXA-48 Carbapenemase. <i>Microorganisms</i> , 2022, 10, 258.	3.6	12
8	Optimization of the rapid carbapenem inactivation method for use with AmpC hyperproducers' authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1210-1211.	3.0	0
9	High Prevalence of OXA-23 Carbapenemase-Producing <i>Proteus mirabilis</i> among Amoxicillin-Clavulanate-Resistant Isolates in France. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0198321.	3.2	8
10	Antimicrobial Resistance in Enterobacterales Recovered from Urinary Tract Infections in France. <i>Pathogens</i> , 2022, 11, 356.	2.8	11
11	<i>Bordetella hinzii</i> Pneumonia in Patient with SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2022, 28, 844-847.	4.3	0
12	<i>Bordetella hinzii</i> Pneumonia in Patient with SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2022, 28, 844-847.	4.3	3
13	Comment on Mitteregger et al. A Variant Carbapenem Inactivation Method (CIM) for <i>Acinetobacter baumannii</i> Group with Shortened Time-to-Result: rCIM-A. <i>Pathogens</i> 2022, 11, 482. <i>Pathogens</i> , 2022, 11, 751.	2.8	1
14	Evaluation of the Novodiag CarbaR+, a Novel Integrated Sample to Result Platform for the Multiplex Qualitative Detection of Carbapenem and Colistin Resistance Markers. <i>Microbial Drug Resistance</i> , 2021, 27, 170-178.	2.0	9
15	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 226-240.	9.1	411
16	Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study. <i>Microorganisms</i> , 2021, 9, 282.	3.6	28
17	Genomic analysis of VIM-2-producing <i>Enterobacter hormaechei</i> subsp. <i>steigerwaltii</i> . <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106285.	2.5	4
18	Polyclonal Dissemination of NDM-1- and NDM-9-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in French Polynesia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	5

#	ARTICLE	IF	CITATIONS
19	<i>In vitro</i> activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014â€“2018 studies in France. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab081.	2.1	10
20	Emergence and Polyclonal Dissemination of OXA-244â€“Producing <i>Escherichia coli</i> , France. <i>Emerging Infectious Diseases</i> , 2021, 27, 1206-1210.	4.3	14
21	Outbreak of OXA-48-producing Enterobacterales in a haematological ward associated with an uncommon environmental reservoir, France, 2016 to 2019. <i>Eurosurveillance</i> , 2021, 26, .	7.0	11
22	Biochemical characterization of OXA-244, an emerging OXA-48 variant with reduced β -lactam hydrolytic activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2024-2028.	3.0	6
23	Optimization of the rapid carbapenem inactivation method for use with AmpC hyperproducers. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2294-2301.	3.0	9
24	Redefining the Origin and Evolution of Chromosomally Encoded <i>bla</i> CTX-M/KLU in the Context of a Revised Taxonomy of Genus <i>Kluyvera</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0242420.	3.2	4
25	Azetidinimines as a novel series of non-covalent broad-spectrum inhibitors of β -lactamases with submicromolar activities against carbapenemases KPC-2 (class A), NDM-1 (class B) and OXA-48 (class D). <i>European Journal of Medicinal Chemistry</i> , 2021, 219, 113418.	5.5	14
26	Detection and Characterization of VIM-52, a New Variant of VIM-1 from a <i>Klebsiella pneumoniae</i> Clinical Isolate. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0266020.	3.2	2
27	KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a <i>Klebsiella pneumoniae</i> ST307 Clinical Isolate. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0116021.	3.2	14
28	Outbreak of CTX-M-15 Extended-Spectrum β -Lactamase-Producing <i>Klebsiella pneumoniae</i> ST394 in a French Intensive Care Unit Dedicated to COVID-19. <i>Pathogens</i> , 2021, 10, 1426.	2.8	13
29	Undetectable Production of the VIM-1 Carbapenemase in an <i>Atlantibacter hermannii</i> Clinical Isolate. <i>Frontiers in Microbiology</i> , 2021, 12, 741972.	3.5	5
30	Optimization of the MALDIxin test for the rapid identification of colistin resistance in <i>Klebsiella pneumoniae</i> using MALDI-TOF MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 110-116.	3.0	33
31	Different phenotypic expression of KPC β -lactamase variants and challenges in their detection. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 769-771.	3.0	16
32	LMB-1 producing <i>Citrobacter freundii</i> from Argentina, a novel player in the field of MBLs. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105857.	2.5	14
33	Characterisation of incompatibility groups and plasmid addiction systems in a collection of multiresistant-producing <i>Klebsiella pneumoniae</i> strains. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105855.	2.5	0
34	Biochemical and Structural Characterization of OXA-405, an OXA-48 Variant with Extended-Spectrum β -Lactamase Activity. <i>Microorganisms</i> , 2020, 8, 24.	3.6	12
35	Carbapenemase-producing Enterobacterales outbreak: Another dark side of COVID-19. <i>American Journal of Infection Control</i> , 2020, 48, 1533-1536.	2.3	44
36	A Lateral Flow Immunoassay for the Rapid Identification of CTX-M-Producing Enterobacterales from Culture Plates and Positive Blood Cultures. <i>Diagnostics</i> , 2020, 10, 764.	2.6	33

#	ARTICLE	IF	CITATIONS
37	Compassionate Use of Cefiderocol to Treat a Case of Prosthetic Joint Infection Due to Extensively Drug-Resistant <i>Enterobacter hormaechei</i> . <i>Microorganisms</i> , 2020, 8, 1236.	3.6	21
38	Evaluation of the Revogene Carba C Assay for Detection and Differentiation of Carbapenemase-Producing Gram-Negative Bacteria. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	8
39	NMR Characterization of the Influence of Zinc(II) Ions on the Structural and Dynamic Behavior of the New Delhi Metallo- β -Lactamase-1 and on the Binding with Flavonols as Inhibitors. <i>ACS Omega</i> , 2020, 5, 10466-10480.	3.5	19
40	Screening of OXA-244 producers, a difficult-to-detect and emerging OXA-48 variant?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2120-2123.	3.0	8
41	Role of Arginine 214 in the Substrate Specificity of OXA-48. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	17
42	Concomitant carriage of KPC-producing and non-KPC-producing <i>Klebsiella pneumoniae</i> ST512 within a single patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2087-2092.	3.0	9
43	A single <i>Proteus mirabilis</i> lineage from human and animal sources: a hidden reservoir of OXA-23 or OXA-58 carbapenemases in Enterobacterales. <i>Scientific Reports</i> , 2020, 10, 9160.	3.3	17
44	Detection of Colistin Resistance in <i>Salmonella enterica</i> Using MALDIxin Test on the Routine MALDI Biotyper Sirius Mass Spectrometer. <i>Frontiers in Microbiology</i> , 2020, 11, 1141.	3.5	12
45	Genetics of Acquired Antibiotic Resistance Genes in <i>Proteus</i> spp.. <i>Frontiers in Microbiology</i> , 2020, 11, 256.	3.5	74
46	Substrate Specificity of OXA-48 after β 5 β 6 Loop Replacement. <i>ACS Infectious Diseases</i> , 2020, 6, 1032-1043.	3.8	10
47	MCR-8 mediated colistin resistance in a carbapenem-resistant <i>Klebsiella pneumoniae</i> isolated from a repatriated patient from Morocco. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105920.	2.5	12
48	First Occurrence of the OXA-198 Carbapenemase in Enterobacterales. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
49	Stepwise evolution and convergent recombination underlie the global dissemination of carbapenemase-producing <i>Escherichia coli</i> . <i>Genome Medicine</i> , 2020, 12, 10.	8.2	40
50	Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales. <i>Frontiers in Medicine</i> , 2020, 7, 616490.	2.6	38
51	Emergence of New Non-Clonal Group 258 High-Risk Clones among <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Isolates, France. <i>Emerging Infectious Diseases</i> , 2020, 26, 1212-1220.	4.3	39
52	Molecular characterization of plasmid-encoded Tripoli MBL 1 (TMB-1) in Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 42-47.	3.0	10
53	Extended-spectrum resistance to β -lactams/ β -lactamase inhibitors (ESRI) evolved from low-level resistant <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 75, 77-85.	3.0	22
54	A 2.5-Year Within-Patient Evolution of <i>Pseudomonas aeruginosa</i> Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	26

#	ARTICLE	IF	CITATIONS
55	Sequential emergence of colistin and rifampicin resistance in an OXA-72- producing outbreak strain of <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 669-673.	2.5	9
56	Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2239-2246.	3.0	48
57	ISAbal1-dependent overexpression of eptA in clinical strains of <i>Acinetobacter baumannii</i> resistant to colistin. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2544-2550.	3.0	19
58	Development and Multicentric Validation of a Lateral Flow Immunoassay for Rapid Detection of MCR-1-Producing <i>Enterobacteriaceae</i> . <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	21
59	Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo- β -Lactamase-Producing Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	92
60	Genetic, Biochemical, and Structural Characterization of CMY-136 β -Lactamase, a Peculiar CMY-2 Variant. <i>ACS Infectious Diseases</i> , 2019, 5, 528-538.	3.8	5
61	False-Positive Carbapenem-Hydrolyzing Confirmatory Tests Due to ACT-28, a Chromosomally Encoded AmpC with Weak Carbapenemase Activity from <i>Enterobacter kobei</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	22
62	Improvement of the Immunochromatographic NG-Test Carba 5 Assay for the Detection of IMP Variants Previously Undetected. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	19
63	Detection of Colistin Resistance in <i>Escherichia coli</i> by Use of the MALDI Biotyper Sirius Mass Spectrometry System. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	38
64	Phylogeny, Resistome, and Virulome of <i>Escherichia coli</i> Causing Biliary Tract Infections. <i>Journal of Clinical Medicine</i> , 2019, 8, 2118.	2.4	3
65	Occurrence of carbapenemase-producing <i>Enterobacteriaceae</i> in Togo, West Africa. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 530-532.	2.5	11
66	Carbapenemase-producing <i>Acinetobacter</i> spp. from environmental sources in a hospital in French Polynesia. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 16, 81-82.	2.2	3
67	Development and validation of a multiplex polymerase chain reaction assay for detection of the five families of plasmid-encoded colistin resistance. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 302-309.	2.5	32
68	Comparison of the Superpolymyxin and ChromID Colistin R Screening Media for the Detection of Colistin-Resistant <i>Enterobacteriaceae</i> from Spiked Rectal Swabs. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
69	Evaluation of the AmpliDiag CarbaR+MCR Kit for Accurate Detection of Carbapenemase-Producing and Colistin-Resistant Bacteria. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	19
70	Evaluation of the CRE and ESBL ELITe MGBA® kits for the accurate detection of carbapenemase- or CTX-M-producing bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 1-7.	1.8	20
71	Evaluation of the rapid carbapenem inactivation method (rCIM): a phenotypic screening test for carbapenemase-producing <i>Enterobacteriaceae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 900-908.	3.0	45
72	A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP- and VIM-type and OXA-48-like carbapenemase-producing <i>Enterobacteriaceae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 909-915.	3.0	162

#	ARTICLE	IF	CITATIONS
73	Evaluation of the AmpliDiag CarbaR+VRE Kit for Accurate Detection of Carbapenemase-Producing Bacteria. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	14
74	A 4.5-Year Within-Patient Evolution of a Colistin-Resistant <i>Klebsiella pneumoniae</i> Carbapenemase-Producing K. pneumoniae Sequence Type 258. <i>Clinical Infectious Diseases</i> , 2018, 67, 1388-1394.	5.8	54
75	Molecular Characterization of OXA-198 Carbapenemase-Producing <i>Pseudomonas aeruginosa</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	23
76	Genomic Insights into Colistin-Resistant <i>Klebsiella pneumoniae</i> from a Tunisian Teaching Hospital. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	52
77	Genomic analysis of in vivo acquired resistance to colistin and rifampicin in <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 266-269.	2.5	20
78	Rapid detection of colistin resistance in <i>Acinetobacter baumannii</i> using MALDI-TOF-based lipidomics on intact bacteria. <i>Scientific Reports</i> , 2018, 8, 16910.	3.3	61
79	Rapid detection and discrimination of chromosome- and MCR-plasmid-mediated resistance to polymyxins by MALDI-TOF MS in <i>Escherichia coli</i> : the MALDIxin test. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3359-3367.	3.0	66
80	Outbreak of IMI-1 carbapenemase-producing colistin-resistant <i>Enterobacter cloacae</i> on the French island of Mayotte (Indian Ocean). <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 416-420.	2.5	17
81	Whole-genome sequencing of NDM-1-producing ST85 <i>Acinetobacter baumannii</i> isolates from Tunisia. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 916-921.	2.5	31
82	Genetic and Biochemical Characterization of OXA-519, a Novel OXA-48-Like β -Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	20
83	Diversity of Carbapenemase-Producing <i>Escherichia coli</i> Isolates in France in 2012-2013. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	59
84	MALDI-TOF for the rapid detection of carbapenemase-producing Enterobacteriaceae: comparison of the commercialized MBT STAR [®] -Carba IVD Kit with two in-house MALDI-TOF techniques and the RAPIDECA [®] CARBA NP. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2352-2359.	3.0	63
85	Detection of GES-5 Carbapenemase in <i>Klebsiella pneumoniae</i> , a Newcomer in France. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	19
86	Performance of the Xpert [®] Carba-R v2 in the daily workflow of a hygiene unit in a country with a low prevalence of carbapenemase-producing Enterobacteriaceae. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 774-777.	2.5	37
87	MCR-1 and OXA-48 <i>In Vivo</i> Acquisition in KPC-Producing <i>Escherichia coli</i> after Colistin Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	74
88	Draft Genome Sequence of NDM-1-Producing <i>Leclercia adecarboxylata</i> . <i>Genome Announcements</i> , 2017, 5, .	0.8	7
89	Comparison of Two Phenotypic Algorithms To Detect Carbapenemase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	8
90	Promoter characterization and expression of the blaKPC-2 gene in <i>Escherichia coli</i> , <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1597-1601.	3.0	18

#	ARTICLE	IF	CITATIONS
91	Evaluation of the \hat{I}^2 -CARBA $\hat{a}_{\hat{c}}$ test, a colorimetric test for the rapid detection of carbapenemase activity in Gram-negative bacilli. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1646-1658.	3.0	60
92	Prospective evaluation of the OKN K-SeT assay, a new multiplex immunochromatographic test for the rapid detection of OXA-48-like, KPC and NDM carbapenemases. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1955-1960.	3.0	58
93	First report of OXA-232-producing <i>Klebsiella pneumoniae</i> strains in Tunisia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 195-197.	1.8	16
94	Chromosome-Encoded Broad-Spectrum Ambler Class A \hat{I}^2 -Lactamase RUB-1 from <i>Serratia rubidaea</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	2
95	Beta-lactamase database (BLDB) \hat{a} €“ structure and function. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 917-919.	5.2	405
96	OXA-244-Producing <i>Escherichia coli</i> Isolates, a Challenge for Clinical Microbiology Laboratories. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	41
97	Chromosomal Amplification of the bla OXA-58 Carbapenemase Gene in a <i>Proteus mirabilis</i> Clinical Isolate. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	38
98	Retrospective and prospective evaluation of the Carbapenem inactivation method for the detection of carbapenemase-producing Enterobacteriaceae. <i>PLoS ONE</i> , 2017, 12, e0170769.	2.5	37
99	Analysis of OXA-204 carbapenemase-producing Enterobacteriaceae reveals possible endoscopy-associated transmission, France, 2012 to 2014. <i>Eurosurveillance</i> , 2017, 22, .	7.0	20
100	Structural and Functional Aspects of Class A Carbapenemases. <i>Current Drug Targets</i> , 2016, 17, 1006-1028.	2.1	115
101	Improvement of the Xpert Carba-R Kit for the Detection of Carbapenemase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3832-3837.	3.2	66
102	Spread of Plasmids Carrying Multiple GES Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5040-5043.	3.2	19
103	First Occurrence of OXA-72-Producing <i>Acinetobacter baumannii</i> in Serbia. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5724-5730.	3.2	23
104	Prospective evaluation of the OXA-48 <i>K</i> -SeT assay, an immunochromatographic test for the rapid detection of OXA-48-type carbapenemases. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1834-1840.	3.0	48
105	Prospective evaluation of an algorithm for the phenotypic screening of carbapenemase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 135-140.	3.0	34
106	Draft Genome Sequence of the <i>Serratia rubidaea</i> CIP 103234 ^T Reference Strain, a Human-Opportunistic Pathogen. <i>Genome Announcements</i> , 2015, 3, .	0.8	11
107	Whole-Genome Sequence of a European Clone II and OXA-72-Producing <i>Acinetobacter baumannii</i> Strain from Serbia. <i>Genome Announcements</i> , 2015, 3, .	0.8	10
108	Efficient Detection of Carbapenemase Activity in Enterobacteriaceae by Matrix-Assisted Laser Desorption Ionization~Time of Flight Mass Spectrometry in Less Than 30 Minutes. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2163-2171.	3.9	105

#	ARTICLE	IF	CITATIONS
109	Genetic and Biochemical Characterization of OXA-405, an OXA-48-Type Extended-Spectrum $\hat{2}$ -Lactamase without Significant Carbapenemase Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3823-3828.	3.2	73
110	Endoscopy-associated transmission of carbapenemase-producing Enterobacteriaceae: return of 5 yearsâ€™ experience. <i>Endoscopy</i> , 2015, 47, 561-561.	1.8	7
111	Evaluation of the RAPIDEC [®] CARBA NP, the Rapid CARB Screen [®] and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3014-3022.	3.0	110
112	First outbreak of OXA-48-positive carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in Constantine, Algeria. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 725-727.	2.5	26
113	Dissemination of Carbapenemase-Producing Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> in Romania. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7100-7103.	3.2	35
114	New Delhi metallo- $\hat{2}$ -lactamase-producing <i>Acinetobacter baumannii</i> : a novel paradigm for spreading antibiotic resistance genes. <i>Future Microbiology</i> , 2014, 9, 33-41.	2.0	60
115	Ceftazidime-susceptible and imipenem-non-susceptible OXA-58-producing <i>Acinetobacter baumannii</i> from the Comoros archipelago. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 297-298.	2.5	5
116	Screening and deciphering antibiotic resistance in <i>Acinetobacter baumannii</i> : a state of the art. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 571-583.	4.4	90
117	Comparative Genomics of IncL/M-Type Plasmids: Evolution by Acquisition of Resistance Genes and Insertion Sequences. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 674-676.	3.2	60
118	Multidrug-Resistant <i>Acinetobacter baumannii</i> Clone, France. <i>Emerging Infectious Diseases</i> , 2013, 19, 822-823.	4.3	41
119	Tn <i>125</i> -Related Acquisition of <i>bla</i> _{NDM} -Like Genes in <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1087-1089.	3.2	184
120	Biochemical and Genetic Characterization of Carbapenem-Hydrolyzing $\hat{2}$ -Lactamase OXA-229 from <i>Acinetobacter bereziniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3923-3927.	3.2	24
121	First Identification of <i>bla</i> _{IMI-1} in an <i>Enterobacter cloacae</i> Clinical Isolate from France. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1664-1665.	3.2	20
122	AbaR-type transposon structures in <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 234-236.	3.0	30
123	Genetic Features of the Widespread Plasmid Coding for the Carbapenemase OXA-48. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 559-562.	3.2	333
124	Genetic support and diversity of acquired extended-spectrum $\hat{2}$ -lactamases in Gram-negative rods. <i>Infection, Genetics and Evolution</i> , 2012, 12, 883-893.	2.3	114
125	Global Spread of Carbapenemase-producing Enterobacteriaceae. <i>Emerging Infectious Diseases</i> , 2011, 17, 1791-1798.	4.3	1,923
126	Carbapenem-Hydrolyzing GES-Type Extended-Spectrum $\hat{2}$ -Lactamase in <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 349-354.	3.2	97

#	ARTICLE	IF	CITATIONS
127	Outbreak of OXA-48-Positive Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Isolates in France. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2420-2423.	3.2	173
128	CTX-M-93, a CTX-M Variant Lacking Penicillin Hydrolytic Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1861-1866.	3.2	21
129	Analysis of the Resistome of a Multidrug-Resistant NDM-1-Producing <i>Escherichia coli</i> Strain by High-Throughput Genome Sequencing. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4224-4229.	3.2	138
130	GES Extended-Spectrum $\hat{\beta}$ -Lactamases in <i>Acinetobacter baumannii</i> Isolates in Belgium. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4872-4878.	3.2	79
131	Worldwide Diversity of <i>Klebsiella pneumoniae</i> That Produce $\hat{\beta}$ -Lactamase <i>bla</i> _{KPC-2} Gene1. <i>Emerging Infectious Diseases</i> , 2010, 16, 1349-1356.	4.3	277
132	Diversity, Epidemiology, and Genetics of Class D $\hat{\beta}$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 24-38.	3.2	546
133	The real threat of <i>Klebsiella pneumoniae</i> carbapenemase-producing bacteria. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 228-236.	9.1	1,334
134	Genetic Structures at the Origin of Acquisition of the $\hat{\beta}$ -Lactamase <i>bla</i> _{KPC} Gene. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1257-1263.	3.2	450
135	Chromosome-Encoded Narrow-Spectrum Ambler Class A $\hat{\beta}$ -Lactamase GIL-1 from <i>Citrobacter gillenii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1365-1372.	3.2	15
136	Genetics and Expression of the Carbapenem-Hydrolyzing Oxacillinase Gene <i>bla</i> OXA-23 in <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1530-1533.	3.2	199
137	Functional Characterization of IS 1999 , an IS 4 Family Element Involved in Mobilization and Expression of $\hat{\beta}$ -Lactam Resistance Genes. <i>Journal of Bacteriology</i> , 2006, 188, 6506-6514.	2.2	111
138	Regional Occurrence of Plasmid-Mediated Carbapenem-Hydrolyzing Oxacillinase OXA-58 in <i>Acinetobacter</i> spp. in Europe. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4885-4888.	3.9	93
139	Outbreak of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Producing the Carbapenemase OXA-23 in a Tertiary Care Hospital of Papeete, French Polynesia. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4826-4829.	3.9	100
140	Structure of the imipenem-hydrolyzing class A $\hat{\beta}$ -lactamase SME-1 from <i>Serratia marcescens</i> . <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2002, 58, 267-274.	2.5	42
141	GES-2, a Class A $\hat{\beta}$ -Lactamase from <i>Pseudomonas aeruginosa</i> with Increased Hydrolysis of Imipenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2598-2603.	3.2	201
142	AmpD Is Required for Regulation of Expression of Nmca, a Carbapenem-Hydrolyzing $\hat{\beta}$ -Lactamase of <i>Enterobacter cloacae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2908-2915.	3.2	19
143	Biochemical Sequence Analyses of GES-1, a Novel Class A Extended-Spectrum $\hat{\beta}$ -Lactamase, and the Class 1 Integron In52 from <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 622-632.	3.2	397
144	Molecular Characterization of OXA-20, a Novel Class D $\hat{\beta}$ -Lactamase, and Its Integron from <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2074-2083.	3.2	69

#	ARTICLE	IF	CITATIONS
145	Activity of mecillinam against carbapenem-resistant Enterobacterales. Journal of Antimicrobial Chemotherapy, 0, , .	3.0	2